2013 Position Development Conference on Bone DensitometryThe Official Positions of the International Society for Clinical Densitometry: Indications of Use and Reporting of DXA for Body Composition
Introduction
The task force addressed questions related to the clinical indications for body composition testing that could be supported by the published literature. Specific areas of focus were indications for body composition testing in persons living with HIV, patients after bariatric surgery, obese patients, anorexia, and sarcopenia. In addition, we searched the literature on other techniques for estimating body composition and contraindications to dual-energy X-ray absorptiometry (DXA) body composition testing. The references obtained were augmented by other pertinent references known by committee members but not appearing in the search strategy. Appendix lists the search terms used and the citations obtained. Relevant publications were downloaded and reviewed; the results collated in a data table. Presentations to the expert panel were formulated from this. The final positions agreed on by the expert panel were then brought into the document with the references supporting the final official positions.
Using DXA technology for body composition analysis has the potential to offer new diagnostic insights for patient disease in a variety of areas. In addition, the technology has the potential to monitor change with therapy or other interventions. Other technologies that measure body composition include computed tomography (CT), magnetic resonance imaging (MRI), bioelectrical impedance analysis (BIA), air/water displacement, and anthropometric measurements. Each of these techniques has unique strengths and limitations, with trade-offs in ease of use, accessibility, accuracy, and comprehensiveness. DXA is well correlated with CT, MRI, and BIA 1, 2, 3, 4, 5, 6 and should be considered when quantitative body composition measurement is desired 7, 8, 9. In some instances, use of body composition technologies other than DXA may be superior 2, 10. For example, CT and MRI offer more detailed measurements of specific regions or tissues, such as visceral adipose fat or fat infiltration of tissues 8, 9. Although most DXA software will allow for an estimate of visceral adipose tissue, the level of detail is inferior to that of CT or MRI 11, 12. Nevertheless, DXA may be preferred as the whole body may be easily quantified, radiation exposure is low, and it is likely to be more accessible and more economical to obtain than CT or MRI 1, 7, 8. As noted earlier, BIA is also widely available for body composition assessment; its advantage over DXA is portability, device cost, and ease of administration (8). Although less portable, air and water displacement systems generate similar measurements using a different technique (13). However, the inability of these methods to independently obtain measurement of more than fat or fat-free mass limits their utility. More recent versions of BIA technology have improved ability to assess regions and differentiate inter- and intracellular water 14, 15. In general, anthropometric methods are useful to assess cardiovascular disease and diabetes risk (16) and are considered crude tools to assess body composition. The strengths and limitations of these technologies are summarized in Table 1.
As DXA is demonstrated to be a viable method to measure body composition, it was deemed appropriate to address the lack of consistent guidelines recommending indications for DXA body composition and for standardized reporting of these measurements. In this endeavor, the lack of well-designed comparative studies of the modalities described earlier is acknowledged as noted in the evidence and strength of recommendation grades associated with these positions. Although there are good data validating and correlating the tools, there are no head-to-head studies evaluating comparability in a specific circumstance. Consequently, in many cases, the guidelines presented in this work will be based on clinical research studies from small numbers of patients and often lack endpoint validation or cost-efficacy data.
The task force was charged with developing recommendations for several conditions and diseases where body composition analysis by DXA may prove valuable. These conditions include people living with HIV, obesity, postbariatric surgery or weight loss, and sarcopenia. Performance athletes may benefit from applications of body composition analysis by DXA as an aid to training, but this has been addressed by others (17) and, consequently, was not addressed by this group.
Section snippets
ISCD Official Position
- •
DXA total body composition with regional analysis can be used in the following conditions: in patients living with HIV to assess fat distribution in those using antiretroviral agents associated with a risk of lipoatrophy (currently stavudine and zidovudine).
Grade: Good-B-W
ISCD Official Position
- •
DXA total body composition with regional analysis can be used in the following conditions: in obese patients undergoing bariatric surgery (or medical, diet, or weight loss regimens with anticipated large weight loss) to assess fat and lean mass changes when weight loss exceeds approximately 10%. The impact on clinical outcomes is uncertain.
Grade: Poor-C-W
ISCD Official Position
- •
DXA total body composition with regional analysis can be used in the following conditions: in patients with muscle weakness or poor physical functioning to assess fat and lean mass. The impact on clinical outcomes is uncertain.
Grade: Fair-C-W
ISCD Official Position
- •
No position could be agreed on at this time.
ISCD Official Position
- •
Pregnancy is a contraindication to DXA body composition. Limitations in the use of clinical DXA for total body composition or bone mineral density are weight over the table limit, recent administration of contrast material, and/or artifact. Radiopharmaceutical agents may interfere with accuracy of results using systems from some DXA manufacturers.
Grade: Fair-B-W
Acknowledgments
The contribution by RAF is partially supported by the US Department of Agriculture under agreement no. 58-1950-0-014. Any opinions, findings, conclusion, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the US Department of Agriculture.
We appreciate the comments received from representatives of instrument manufacturers including Kevin Wilson, Tom Sanchez, and David Ergun.
References (137)
- et al.
Validation of longitudinal DXA changes in body composition from pre- to mid-adolescence using MRI as reference
J Clin Densitom
(2011) - et al.
Comparison of dual-energy X-ray absorptiometry and magnetic resonance imaging-measured adipose tissue depots in HIV-infected and control subjects
Am J Clin Nutr
(2008) - et al.
Comparison of body composition by bioelectrical impedance and dual-energy x-ray absorptiometry in overweight/obese postmenopausal women
J Clin Densitom
(2009) - et al.
Comparisons of body-composition prediction accuracy: a study of 2 bioelectric impedance consumer devices in healthy Chinese persons using DXA and MRI as criteria methods
J Clin Densitom
(2011) - et al.
Assessment of analytical methods used to measure changes in body composition in the elderly and recommendations for their use in phase II clinical trials
J Nutr Health Aging
(2011) - et al.
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial
Lancet
(2004) - et al.
Reproducibility of DXA estimations of body fat in HIV lipodystrophy: implications for clinical research
J Clin Densitom
(2005) - et al.
“Buffalo hump” in men with HIV-1 infection
Lancet
(1998) - et al.
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study
Lancet
(2003) - et al.
Is obesity bad for older persons? A systematic review of the pros and cons of weight reduction in later life
J Am Med Dir Assoc
(2008)
Weight loss in obese adults 65 years and older: a review of the controversy.
Exp Gerontol
Preferential loss of central (trunk) adiposity in adolescents and young adults after laparoscopic gastric bypass
Surg Obes Relat Dis
Obesity increases precision errors in dual-energy X-ray absorptiometry measurements
J Clin Densitom
The relationship of physical activity (PA) and walking with sarcopenia in Korean males aged 60 years and older using the Fourth Korean National Health and Nutrition Examination Survey (KNHANES IV-2, 3), 2008-2009
Arch Gerontol Geriatr
Body composition, dietary intake, and energy expenditure after laparoscopic Roux-en-Y gastric bypass and laparoscopic vertical banded gastroplasty: a randomized clinical trial
Ann Surg
Comparison of DXA and CT in the assessment of body composition in premenopausal women with obesity and anorexia nervosa
Obesity (Silver Spring)
A critical evaluation of body composition modalities used to assess adipose and skeletal muscle tissue in cancer
Appl Physiol Nutr Metab
Body composition analysis techniques in the aged adult: indications and limitations
Curr Opin Clin Nutr Metab Care
Are dual-energy X-ray absorptiometry regional estimates associated with visceral adipose tissue mass?
Int J Obes Relat Metab Disord
Dual-energy X-ray absorptiometry for quantification of visceral fat
Obesity (Silver Spring)
Dual-energy X-ray performs as well as clinical computed tomography for the measurement of visceral fat
Obesity (Silver Spring)
Development of methods for body composition studies
Phys Med Biol
Analytic assessment of the various bioimpedance methods used to estimate body water
J Appl Physiol
Extracellular water may mask actual muscle atrophy during aging
J Gerontol A Biol Sci Med Sci
Techniques of body composition assessment: a review of laboratory and field methods
Res Q Exerc Sport
Current status of body composition assessment in sport: review and position statement on behalf of the ad hoc research working group on body composition health and performance, under the auspices of the I.O.C. Medical Commission
Sports Med
Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue
HIV Clin Trials
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384
J Acquir Immune Defic Syndr
Changes in body fat measured by DEXA in patients taking different formulations of stavudine
HIV Clin Trials
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides
AIDS
Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s
Clin Infect Dis
Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial
J Acquir Immune Defic Syndr
A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity
Antivir Ther
Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial
Antivir Ther
Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA)
Clin Infect Dis
Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine–a Staccato trial substudy
J Antimicrob Chemother
Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomized clinical trial (the PIILR study)
HIV Clin Trials
A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy
J Acquir Immune Defic Syndr
Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial
JAMA
The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters
AIDS
The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy
HIV Med
Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences
Clin Infect Dis
Multidisciplinary approach to the treatment of metabolic and morphologic alterations of HIV-related lipodystrophy
HIV Clin Trials
Metabolic effects of a growth hormone-releasing factor in patients with HIV
N Engl J Med
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension
J Acquir Immune Defic Syndr
Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy
J Acquir Immune Defic Syndr
Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients
J Acquir Immune Defic Syndr
Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone
HIV Clin Trials
Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial
Ann Intern Med
Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio
AIDS
Cited by (76)
Obesity and body mass index: Past and future considerations in osteoarthritis research
2024, Osteoarthritis and CartilagePositions of The International Society for Clinical Densitometry and Their Etiology: A Scoping Review
2023, Journal of Clinical DensitometryBioelectrical impedance analysis as an alternative to dual-energy x-ray absorptiometry in the assessment of fat mass and appendicular lean mass in patients with obesity
2022, NutritionCitation Excerpt :Although magnetic resonance imaging, computed tomography (CT) scans, or dual-energy x-ray absorptiometry (DXA) have been considered valid reference methods, they are not easily available in clinical practice, and CT and DXA may involve x-ray exposure [1]. DXA should be performed no more than twice per year, which limits its use for body composition measurement [3]. Bioelectrical impedance analysis (BIA) has been proposed as an alternative tool in the absence of confounding fluid balance abnormalities as it is portable, easy to use, relatively low cost, and free from radiation [4–6].